NCT04764994

Brief Summary

Stroke is the third commonest cause of death and is probably the commonest cause of severe disability. Upper limb recovery after stroke is unacceptably poor with only 50% of stroke survivors likely to regain some functional use. In many disabilities, the rehabilitation process is of long duration and clinicians face the challenge of identifying a variety of meaningful and motivating intervention tasks that may be adapted and graded to facilitate this process.. Motor learning models emphasize that self-generated voluntary actions should be used and repeated in playful and motivational settings and that the difficulties of the task have to be at an appropriate level for successful learning. Motivation to use the hemiplegic upper extremity was considered to be the most important factor in guaranteeing intense practice and was achieved through the patient's individual inner drive and motivation for play. Virtual reality-based therapy is one of the most innovative and developments in rehabilitation technology. Enhanced feedback provided by a virtual reality system has been shown to promote motor learning in normal subjects. Interaction with objects in a virtual environment (VE) through grasping and manipulation is an important feature of future virtual reality simulations. Until now, there has been limited research involving the inclusion of virtual reality gaming systems in neuro-rehabilitation for hemiplegic patients. So the purpose of this study will be evaluation of the efficacy of virtual reality technology on improving the function of the involved upper extremity in Saudi patients having stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable stroke

Timeline
Completed

Started Feb 2021

Shorter than P25 for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2021

Completed
5 days until next milestone

Study Start

First participant enrolled

February 18, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 21, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 20, 2021

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2021

Completed
Last Updated

November 8, 2022

Status Verified

November 1, 2022

Enrollment Period

5 months

First QC Date

February 13, 2021

Last Update Submit

November 5, 2022

Conditions

Keywords

HemiplegiaVirtual-RealityUpper Limb FunctionsBalance Performance

Outcome Measures

Primary Outcomes (3)

  • Change in the score of Fugl-Meyer Assessment Scale of Upper-Extremity (scale that assess the change in upper extremity motor functions)

    The Fugl-Meyer Assessment of Upper Extremity (FMA-UE) is a stroke-specific, performance-based impairment index. It measures the movement, coordination and reflex action of the shoulder, elbow, forearm, wrist and hand. The scale includes 33 items divided into 4 subscales: (A) shoulder/elbow, 18 items, (B) wrist, 5 items, (C) hand, 7 items, and (D) coordination/speed, 3 items. Each item is scored on an ordinal 3-point scale, where 2 points are assigned when the movement is performed fully, 1 point when performed partially, and 0 points when the movement cannot be performed. A total score of 66 indicates better sensorimotor function. Thus, the higher the score a patient will get after completion of the treatment program compared to the baseline score, the better the improvement in upper extremity motor functions.

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.] (i.e. Difference between Fugl-Meyer Assessment Scale Score of Upper-Extremity at both baseline and completion of 12 weeks of intervention)

  • Change in the score of The Action Research Arm Test (test that assess the change in upper extremity functions)

    The Action Research Arm Test (ARAT) is an evaluative measure to assess specific changes in limb function among individuals with hemiplegia. It assesses a patient's ability to handle objects differing in size, weight and shape and therefore can be considered to be an arm-specific measure of activity limitation. The ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement. The ARAT is scored on a four-level ordinal scale (0-3): 0 = cannot perform any part of the test, 1 = performs partially, 2 = take long time to complete the test, and 3 = performs the test normally. The total score on the ARAT ranges from 0 to 57, with the lowest score indicating that no movements can be performed, and the upper score indicating normal performance. Thus, the higher the score a patient will get after completion of the treatment program compared to the baseline score, the better the improvement in upper extremity motor functions.

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between The Action Research Arm Test Score at both baseline and completion of 12 weeks of intervention)

  • Change in the score of The Wolf Motor Function Test (test that assess the change in upper extremity motor ability)

    The Wolf Motor Function Test (WMFT) is designed to assess upper extremity motor abilities in patients with stroke through timed and functional tasks. The WMFT consists of 15 timed items (6 items involve timed functional tasks, and 9 items consist of analyzing movement quality when completing various tasks), in addition to 2 items (7\&14) are measures of strength. The examiner should test the less affected upper extremity followed by the most affected side. The 15 timed items are rated on a 6-point functional ability scale (0-5), score (0) means the patient is unable to use UE being tested while score (5) means the patient is able to use it and movement appears to be normal. The total score on the WMFT ranges from 0 to 75. Lower scores are indicative of lower functioning levels. Thus, the higher the score a patient will get after completion of the treatment program compared to the baseline score, the better the improvement in upper extremity (UE) motor abilities.

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between The Wolf Motor Function Test Score at both baseline and completion of 12 weeks of intervention)

Secondary Outcomes (5)

  • Change in the Overall Stability Indices {percentage value (%)} for Postural Stability Test (test that assess the change in postural stability)

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between the overall stability indices score at both baseline and completion of 12 weeks of intervention)

  • Change in the Overall Stability Index {percentage value (%)}, and Time of Control {seconds} for Limit of Stability Test (test that assess the change in balance ability)

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between the overall stability index and the time of control at both baseline and completion of 12 weeks of intervention)

  • Change in the cadence (step/minute) (which indicate the change of walking ability in patients with stroke).

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between cadence at both baseline and completion of 12 weeks of intervention)

  • Change in the Gait Velocity (meter /second) (which indicate the change of gait function in patients with stroke).

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between gait velocity at both baseline and completion of 12 weeks of intervention)

  • Change in the Hand Grip Strength of the Involved Upper Extremity (pounds) (which indicate the change of the strength of the involved hand muscles in patients with stroke).

    [Time Frame: Data collected at baseline, and 12 weeks after intervention commencement.](i.e. Difference between hand grip strength at both baseline and completion of 12 weeks of intervention)

Study Arms (2)

Control Group

ACTIVE COMPARATOR

Participants who will participated in the control group will receive a conventional physical therapy program for two hours. It will include two parts, each of them will be one hour and 15 minutes rest in between. The first part will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises. The second part will include: arm-reaching tasks, arm-hand tasks, manipulative tasks (grasping and release activities) and upper limb self-dependent tasks and the inclusion of the more affected upper limb in functional tasks of daily living activities. The conventional treatment program will be applied for both groups by therapists, experienced in stroke rehabilitation. Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks.

Other: Conventional Physical Therapy Program

Study Group

EXPERIMENTAL

Participants of study group will receive two hours treatment program that will include three parts, the first and the second parts (similar to that will be applied for participants in control group) will be together for one hour following by 15 minutes rest, then the third part will apply for one hour. The third part of the program will be one hour virtual reality intervention program by using Armeo Spring to simulate a range of upper limb tasks related to arm-reaching to target, reach and grasp (arm-hand activities) and manipulative tasks through using different games and soft-wares. The conventional treatment part of the program will be applied by therapists, experienced in stroke rehabilitation. The virtual reality part of the program will be applied by another experienced physiotherapists, who are well trained in using Armeo Spring System. Treatment frequency (Dose): Therapeutic intervention will be carried out three sessions per week for twelve successive weeks.

Device: Armeo®Spring ((Task-oriented upper extremity rehabilitation system)Other: Conventional Physical Therapy Program

Interventions

Armeo®Spring is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The Armeo Spring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury or other neurological diseases and injuries. It combines an adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.

Study Group

This intervention t will include: muscle facilitation exercises, proprioceptive neuromuscular facilitation exercises, strengthening activities, stretching exercises and postural reactions exercises.

Control GroupStudy Group

Eligibility Criteria

Age50 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Forty Saudi stroke male participants will be included in this study.
  • The participating participants will have a confirmed diagnosis of stroke confirmed by magnetic resonance images (MRIs) obtained from medical records or personal physicians.
  • They should be medically stable and will have neither serious nor recurring medical complications according to the medical report signed by their physician.
  • The age of participants will be between 50 to 60 years.
  • Participants of both genders will be recruited
  • The participants will be selected to be in spastic phase, 6-24 months following a first stroke.
  • The degree of spasticity in upper extremity according to Modified Ashworth Scale will ranged between grades 1,1+\&2.
  • The included participants should be cognitively competent and able to understand and follow instructions.
  • The participants will associated with neither fixed stiffness in shoulder, elbow, wrist and fingers joints nor major rotational mal-alignments in the upper limbs.
  • The patient should have the ability to extend the wrist at least 20° and fingers 10° from full flexion. This range will allow participants to engage easily in performing a designed program.
  • Also they should have no serious problems affecting balance performance other than spasticity due to stroke.
  • During the study, participants will not receive any treatment to improve involved upper limb functions other than the study intervention.

You may not qualify if:

  • Participants will be excluded from study if they have:
  • Cognitive decline (Mini-Mental State Examination \< 23 points). Due to the requirements of the ARMEO system.
  • Shoulder pain on a visual analogue scale of \> 6/10.
  • Spasticity score ≥ 2 according to the Modified Ashworth Scale
  • Conditions affecting their participations in this study (e.g. cardiac, respiratory, seizures or arthritic problems)
  • Visual problems that may prevent them from performing the intervention
  • Botulinum toxin in the upper extremity musculature six months before baseline assessment or who wished to receive it within the period of study,
  • Muscle-tone control medications before baseline assessment or who wished to receive it within the period of study.
  • A cardiac pacemaker as the electromagnetic motion tracker used within the virtual reality system might interfere with such devices.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ehab Abd El Kafy

Mecca, 21955, Saudi Arabia

Location

MeSH Terms

Conditions

StrokeHemiplegia

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ehab Abd El Kafy, Ph.D

    Professor of Physical Therapy -Umm Al Qura University.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The evaluators who will perform all assessments throughout the study will not take part in the intervention program. They also will not been informed about which group; each evaluated patient will belong (blind assessors).
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Physical Therapy

Study Record Dates

First Submitted

February 13, 2021

First Posted

February 21, 2021

Study Start

February 18, 2021

Primary Completion

July 20, 2021

Study Completion

August 15, 2021

Last Updated

November 8, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will share

* Individual participant data underlying published results only. * The data available is Case-by-case basis at the discretion of Primary Sponsor

Shared Documents
SAP
Time Frame
Start Date: Beginning one year following main results publication End Date: Ending two years following main results publication
Access Criteria
Data can be obtained by Principal Investigator Email Address: emkafy@uqu.edu.sa

Locations